back to top

Dendreon Investors Will Finally See if Controversial Prostate Cancer Treatment, Provenge Will Make It to the Market

Dendreon Corp. (DNDN) has reached the endline. The biotechnology company’s investors will finally see if the controversial prostate cancer treatment, Provenge, is likely to make it to the market after waiting for two years. The outcome will decide the fate of the Seattle drug developer.

Posted on
This post was created by a member of BuzzFeed Community, where anyone can post awesome lists and creations. Learn more or post your buzz!